BeiGene
ONC
#731
Rank
C$37.13 B
Marketcap
$317.13
Share price
-0.76%
Change (1 day)
76.28%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : C$3.58 Billion

According to BeiGene 's latest financial reports the company's total liabilities are C$3.58 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31C$3.71 B23.49%
2023-12-31C$3.00 B11.07%
2022-12-31C$2.70 B-11.56%
2021-12-31C$3.06 B38.71%
2020-12-31C$2.20 B166.66%
2019-12-31C$0.82 B22.53%
2018-12-31C$0.67 B48.36%
2017-12-31C$0.45 B540.58%
2016-12-31C$71.09 M20.75%
2015-12-31C$58.87 M82.16%
2014-12-31C$32.32 M-39.9%
2013-12-31C$53.78 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
C$16.81 M-99.53%๐Ÿ‡บ๐Ÿ‡ธ USA
C$1.15 B-67.75%๐Ÿ‡บ๐Ÿ‡ธ USA